Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results
Open Access
- 17 April 2020
- journal article
- research article
- Published by BMJ in British Journal of Ophthalmology
- Vol. 105 (2), 253-257
- https://doi.org/10.1136/bjophthalmol-2020-316176
Abstract
Background/aims To evaluate the long-term effects of treat-and-extend dosing of ranibizumab with and without navigated focal laser for diabetic macular oedema (DME). Methods This is a multicentre, randomised clinical trial where 150 eyes were randomised into three cohorts; Monthly (n=30), TReat and EXtend without macular laser photocoagulation (TREX; n=60), and treat and extend with angiography-GuIded macular LAser photocoagulation (GILA; n=60). During the first 2 years, eyes either received ranibizumab 0.3 mg every 4 weeks or underwent treat-and-extend ranibizumab with or without angiography-guided laser therapy. In the third year, all eyes were treated as needed with ranibizumab for >5 letters vision loss or if the central retinal thickness (CRT) was >325 µm, and all eyes were eligible to receive focal laser. Results 109 eyes (73%) completed the 3-year end-point. At week 156, mean best-corrected visual acuity (BCVA) and CRT improved by 6.9, 9.7, 9.5 letters (p=0.60) and 129, 138, 165 µm (p=0.39), in the Monthly, TREX and GILA cohorts, respectively. These improvements were reached prior to week 104 and no significant changes occurred from week 104 to week 156 (BCVA: p=0.34; CRT: p=0.36). The mean number of injections in the third year was 3.0, 3.1, and 2.4 in the Monthly, TREX and GILA cohorts, respectively (p=0.56). 86 eyes (79%) required at least one ranibizumab injection in the third year. Conclusion The improvements achieved after 2 years of treat-and-extend ranibizumab for DME were maintained in the third year with a mean of 3 intravitreal injections. Trial registration number FDA IND 119146, NCT01934556.Keywords
Funding Information
- Genentech (ML28724)
This publication has 14 references indexed in Scilit:
- Randomized Trial of Treat and Extend Ranibizumab With and Without Navigated Laser Versus Monthly Dosing for Diabetic Macular Edema: TREX-DME 2-Year OutcomesAmerican Journal of Ophthalmology, 2019
- Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension StudyAmerican Journal of Ophthalmology, 2017
- Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular EdemaOphthalmology, 2016
- Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular EdemaOphthalmology, 2016
- Outcomes with As-Needed Ranibizumab after Initial Monthly TherapyOphthalmology, 2015
- Intravitreal Aflibercept for Diabetic Macular EdemaOphthalmology, 2015
- Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial ResultsOphthalmology, 2014
- Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III TrialsOphthalmology, 2013
- Two-Year Safety and Efficacy of Ranibizumab 0.5 mg in Diabetic Macular EdemaOphthalmology, 2013
- Diabetic Retinopathy and Diabetic Macular EdemaDiabetes Care, 2003